Merck, SpringWorks

Germany's Merck in advanced talks to acquire US biotech firm SpringWorks
(Corrects third to last paragraph to say "the erosion from LOEs (loss of exclusivity)", not "from LOEs (levels of evidence)") By Sabrina Valle and Patricia Weiss NEW YORK/FRANKFURT (Reuters) -Merck KGaA,
Germany’s Merck in Talks to Buy SpringWorks Therapeutics
Germany’s Merck KGaA is in advanced talks for a potential acquisition of SpringWorks Therapeutics, a U.S. biopharmaceutical company that specializes in rare diseases and cancer.
Merck's Strategic Move: Advanced Talks to Acquire SpringWorks Therapeutics
Merck KGaA is in advanced negotiations to acquire U.S. biotech firm SpringWorks Therapeutics. While a deal isn't finalized, SpringWorks' share value surged following the talks. This acquisition could bolster Merck's cancer treatment offerings amidst recent setbacks in drug trials and increased activity in the U.
Exclusive-Germany's Merck KGaA in talks to buy US biotech firm Springworks, sources say
Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker Springworks Therapeutics, according to people familiar with the matter.
SpringWorks jumps as Merck KGaA reportedly in talks to acquire company
Merck KGaA (MKGAY), the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases drugmaker
FiercePharma15h
UPDATE: Merck KGaA sets its sights on acquisition of Ogsiveo maker SpringWorks
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Merck & Co. Inc. stock underperforms Thursday when compared to competitors
Shares of Merck & Co. Inc. MRK slid 1.81% to $88.05 Thursday, on what proved to be an all-around mixed trading session for ...
Why Merck Stock Is Plummeting Today
Merck's stock sank after the company reported fourth-quarter and year-end 2024 earnings this morning. Although it narrowly ...
STAT7d
Merck’s earnings miss focused attention on Gardasil. The real issue is Keytruda
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck Stock Slumps as Q4 Profits, 2025 Forecast Fall Short
Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...
Better High-Yield Dividend Stock: Pfizer vs. Merck
Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.
AOL7d
Merck beats estimates on Q4 earnings, stock slides on tepid 2025 guidance
Merck reported $64.2 billion in sales for 2024, a 7% increase compared with 2023. That is near Wall Street's consensus of ...